Global PEG-modified Drugs Market Report, History and Forecast 2018-2034, Breakdown Data by Companies, Key Regions, Types and Application
Published on: 2024-01-04 | No of Pages : 400 | Industry : Medical
Publisher : MRA | Format : PDF
Global PEG-modified Drugs Market Report, History and Forecast 2018-2034, Breakdown Data by Companies, Key Regions, Types and Application
Polyethylene glycol modified drug refers to a method of drug modification that combines polyethylene glycol molecules with drug molecules to improve the properties, pharmacokinetics and pharmacodynamic properties of drugs. This modification is often used to improve drug solubility, stability, bioavailability, and drug distribution.
PEG-modified Drugs report published by MRAResearch reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global PEG-modified Drugs market is projected to reach US$ million in 2033, increasing from US$ million in 2022, with the CAGR of % during the period of 2023 to 2033. Demand from Cancer Treatment and Diabetes Treatment are the major drivers for the industry.
North America, Europe and Asia Pacific are the key regions for PEG-modified Drugs industry. Among those areas, stimulated by rigid demand from downstream industries, Asia Pacific is estimated to experience fast growth, with the CAGR of % during 2023 to 2033.
Globally, PEG-modified Drugs key companies include Merck Sharp & Dohme, Baxalta Inc., Amgen Inc., Roche, UCB S.A., Enzon, Horizon Pharma Plc, Biogen Inc. and Qilu Pharmaceutical Co., Ltd., etc. Merck Sharp & Dohme, Baxalta Inc., Amgen Inc. are top 3 players and held % share in total in 2022.
PEG-modified Drugs can be divided into PEG Amidation, PEGylation, PEG Peptidation and PEG Etherification, etc. PEG Amidation is the mainstream product in the market, accounting for % share globally in 2022.
PEG-modified Drugs is widely used in various fields, such as Cancer Treatment, Diabetes Treatment, Immunomodulatory and Anti-inflammatory Treatment, etc. Cancer Treatment provides greatest supports to the PEG-modified Drugs industry development. In 2022, global % share of PEG-modified Drugs went into Cancer Treatment filed.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2033), aims to help readers to get a comprehensive understanding of global PEG-modified Drugs market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Companies, Type, Application and Regions Listed in the Report
Merck Sharp & Dohme
Baxalta Inc.
Amgen Inc.
Roche
UCB S.A.
Enzon
Horizon Pharma Plc
Biogen Inc.
Qilu Pharmaceutical Co., Ltd.
CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.
Changchun Genescience Pharmaceutical Co., Ltd.
Xiamen Amoytop Biotech Co., Ltd.
Jiangsu Hengrui Pharmaceuticals Co., Ltd.
Hansoh Pharmaceuticak Group Co.,Ltd.
SunBio
Xiamen Sano banger Biotechnology Co., Ltd
Segment by Type
PEG Amidation
PEGylation
PEG Peptidation
PEG Etherification
Other Combinations
Cancer Treatment
Diabetes Treatment
Immunomodulatory
Anti-inflammatory Treatment
Others
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Latin America
Mexico
Brazil
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the PEG-modified Drugs market further
Chapter 1Global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2033).
Chapter 2Product Types and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2023.
Chapter 3Product Application and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2023.
Chapter 4Company Competition Status, Detailed analysis of Product Name companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5Companies’ Outline, covering company’s basic information, PEG-modified Drugs introduction, etc. PEG-modified Drugs Revenue and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 6 to 10Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa by revenue.
Chapter 11Market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry.
Chapter 12MRAResearch’s Conclusions of PEG-modified Drugs market based on comprehensive survey.
Chapter 13Methodology and Data Sources adopted by MRAResearch.
PEG-modified Drugs report published by MRAResearch reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global PEG-modified Drugs market is projected to reach US$ million in 2033, increasing from US$ million in 2022, with the CAGR of % during the period of 2023 to 2033. Demand from Cancer Treatment and Diabetes Treatment are the major drivers for the industry.
North America, Europe and Asia Pacific are the key regions for PEG-modified Drugs industry. Among those areas, stimulated by rigid demand from downstream industries, Asia Pacific is estimated to experience fast growth, with the CAGR of % during 2023 to 2033.
Globally, PEG-modified Drugs key companies include Merck Sharp & Dohme, Baxalta Inc., Amgen Inc., Roche, UCB S.A., Enzon, Horizon Pharma Plc, Biogen Inc. and Qilu Pharmaceutical Co., Ltd., etc. Merck Sharp & Dohme, Baxalta Inc., Amgen Inc. are top 3 players and held % share in total in 2022.
PEG-modified Drugs can be divided into PEG Amidation, PEGylation, PEG Peptidation and PEG Etherification, etc. PEG Amidation is the mainstream product in the market, accounting for % share globally in 2022.
PEG-modified Drugs is widely used in various fields, such as Cancer Treatment, Diabetes Treatment, Immunomodulatory and Anti-inflammatory Treatment, etc. Cancer Treatment provides greatest supports to the PEG-modified Drugs industry development. In 2022, global % share of PEG-modified Drugs went into Cancer Treatment filed.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2033), aims to help readers to get a comprehensive understanding of global PEG-modified Drugs market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Companies, Type, Application and Regions Listed in the Report
By Company
Merck Sharp & Dohme
Baxalta Inc.
Amgen Inc.
Roche
UCB S.A.
Enzon
Horizon Pharma Plc
Biogen Inc.
Qilu Pharmaceutical Co., Ltd.
CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.
Changchun Genescience Pharmaceutical Co., Ltd.
Xiamen Amoytop Biotech Co., Ltd.
Jiangsu Hengrui Pharmaceuticals Co., Ltd.
Hansoh Pharmaceuticak Group Co.,Ltd.
SunBio
Xiamen Sano banger Biotechnology Co., Ltd
Segment by Type
PEG Amidation
PEGylation
PEG Peptidation
PEG Etherification
Other Combinations
Segment by Application
Cancer Treatment
Diabetes Treatment
Immunomodulatory
Anti-inflammatory Treatment
Others
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Latin America
Mexico
Brazil
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the PEG-modified Drugs market further
Chapter 1Global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2033).
Chapter 2Product Types and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2023.
Chapter 3Product Application and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2023.
Chapter 4Company Competition Status, Detailed analysis of Product Name companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5Companies’ Outline, covering company’s basic information, PEG-modified Drugs introduction, etc. PEG-modified Drugs Revenue and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 6 to 10Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa by revenue.
Chapter 11Market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry.
Chapter 12MRAResearch’s Conclusions of PEG-modified Drugs market based on comprehensive survey.
Chapter 13Methodology and Data Sources adopted by MRAResearch.
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices